Chronic Pulmonary Hypertension Market Expected to rise, 2034 | COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market

The Chronic Pulmonary Hypertension market growth is driven by factors like increase in the prevalence of Chronic Pulmonary Hypertension, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Pulmonary Hypertension market report [https://www.delveinsight.com/report-store/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Pulmonary Hypertension market size, share, Chronic Pulmonary Hypertension epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Pulmonary Hypertension market size growth forward.

Some of the key highlights from the Chronic Pulmonary Hypertension Market Insights Report:

*
Several key pharmaceutical companies, including COMPASS Pathways, Homeostasis Therapeutics, LLC, and others, are developing novel products to improve the Chronic Pulmonary Hypertension treatment outlook.

*
In January 2025, AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for treating pulmonary arterial hypertension (PAH), a rare and life-threatening condition characterized by high blood pressure in the lung arteries, which can lead to right-sided heart failure.

*
In December 2024, Nicox announced that its Denali Phase III trial, assessing the efficacy and safety of NCX470 for patients with open-angle glaucoma or ocular hypertension, has completed enrollment in China, and screening has concluded.

*
In November 2024, MediPrint Ophthalmics revealed the results of its Phase IIb clinical trial for LL-BMT1. The trial utilized a new 3D-printed, drug-eluting contact lens for continuous delivery of bimatoprost and hyaluronic acid, successfully meeting all the Phase IIb endpoints.

*
The prevalence of chronic pulmonary hypertension is expected to rise due to factors such as aging populations, increasing obesity rates, better survival rates among premature infants, environmental influences, genetic factors, improved diagnostics, and a rise in comorbidities.

*
In 2023, the US represented the largest share of diagnosed chronic pulmonary hypertension patients in the 7MM, with 42%, followed by Japan, which accounted for around 16% of cases. Among European countries, the UK had the highest number of cases, representing approximately 11% of the total 7MM cases.

*
In 2023, the chronic pulmonary hypertension market was the largest in the US, with a market size of about USD 15,700 million, a figure expected to grow by 2034.

*
Despite the high prevalence, with around 42,476 thousand cases in the 7MM in 2023, the market for chronic pulmonary hypertension treatment remains limited, with few therapies specifically targeting the condition. However, emerging therapies could significantly impact the market, potentially driving substantial growth.

*
As per DelveInsight analysis, the Chronic Pulmonary Hypertension market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Pulmonary Hypertension Market Landscape [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Pulmonary Hypertension Overview

Chronic pulmonary hypertension is a condition characterized by high blood pressure in the lungs, which places strain on the heart and can lead to severe symptoms like shortness of breath and fatigue. It is classified into five groups: Group 1 includes pulmonary arterial hypertension (PAH), Group 2 is pulmonary hypertension caused by left heart disease, Group 3 is pulmonary hypertension linked to lung diseases and/or hypoxia, Group 4 refers to chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unknown or multifactorial causes. Early detection and proper treatment are essential to improve outcomes and quality of life. Diagnosing chronic pulmonary hypertension involves a combination of clinical assessment, imaging, and specialized tests. Challenges can arise due to the nonspecific nature of the symptoms and the need to differentiate pulmonary hypertension from other cardiovascular and respiratory conditions. Diagnostic methods include echocardiography to evaluate heart function and estimate pulmonary artery pressure, followed by confirmatory tests like right heart catheterization, which directly measures pulmonary artery pressures. Accurate interpretation of results can be challenging, especially in cases where other heart or lung conditions are present, requiring a thorough differential diagnosis.

Do you know the treatment paradigms for different countries? Download our Chronic Pulmonary Hypertension Market Sample Report [https://www.delveinsight.com/report-store/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Pulmonary Hypertension Epidemiology Insights

*
The number of chronic pulmonary hypertension cases in the US is projected to grow at a significant compound annual growth rate (CAGR) by 2034, starting from approximately 17,910 thousand cases in 2023.

*
In Europe, Germany had the highest prevalence of chronic pulmonary hypertension, accounting for 26% of cases, followed by the UK in 2023. Conversely, Spain had the lowest prevalence, with around 15% of the total diagnosed cases of chronic pulmonary hypertension in the same year.

Chronic Pulmonary Hypertension Epidemiology Segmentation

DelveInsight's Chronic Pulmonary Hypertension market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Pulmonary Hypertension historical patient pools and forecasted Chronic Pulmonary Hypertension patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Pulmonary Hypertension Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Chronic Pulmonary Hypertension Prevalence

*
Age-Specific Chronic Pulmonary Hypertension Prevalence

*
Gender-Specific Chronic Pulmonary Hypertension Prevalence

*
Diagnosed and Treatable Cases of Chronic Pulmonary Hypertension

Visit for more @ Chronic Pulmonary Hypertension Epidemiological Insights [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Pulmonary Hypertension Market Outlook

Phosphodiesterase-5 (PDE-5) inhibitors like Sildenafil and Tadalafil help reduce vascular smooth muscle cell proliferation and promote vasodilation. Endothelin receptor antagonists, including Ambrisentan, Bosentan, and Macitentan, counteract vasoconstriction and smooth muscle cell growth in the pulmonary arteries. Commonly used calcium channel blockers, such as Nifedipine, diltiazem, and amlodipine, are recommended for treating Pulmonary Arterial Hypertension (PAH). Prostacyclins like epoprostenol, treprostinil, and iloprost improve functional capacity and survival in PAH patients.

Additionally, IP prostacyclin receptor agonists, which activate the prostacyclin pathway, are also used for chronic pulmonary hypertension (PH). Endothelin receptor antagonists reduce endothelin-1 levels, which cause constriction and changes in the pulmonary blood vessels in PAH patients.

PDE-5 inhibitors and soluble guanylate cyclase (sGC) stimulators help lower enzyme levels that produce nitric oxide (NO), a substance that relaxes pulmonary blood vessels. By increasing cyclic GMP levels, these drugs promote vasodilation. PDE-5 inhibitors prevent the breakdown of cyclic GMP, while sGC stimulators enhance cyclic GMP production when NO binds to the sGC enzyme, making them effective treatments for PAH.

Chronic Pulmonary Hypertension Marketed Drugs

*
ADEMPAS (riociguat): Bayer

Chronic Pulmonary Hypertension Emerging Drugs

*
CS1: Cereno Scientific AB

Chronic Pulmonary Hypertension Key Companies

*
COMPASS Pathways, Homeostasis Therapeutics, LLC, and others

For more information, visit Chronic Pulmonary Hypertension Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Pulmonary Hypertension Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Pulmonary Hypertension, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Pulmonary Hypertension epidemiology in the 7MM

*
Chronic Pulmonary Hypertension marketed and emerging therapies

*
Chronic Pulmonary Hypertension companies

*
Chronic Pulmonary Hypertension market drivers and barriers

Table of Contents:

1 Chronic Pulmonary Hypertension Market Key Comprehensive Insights

2 Chronic Pulmonary Hypertension Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Pulmonary Hypertension

4 Chronic Pulmonary Hypertension Market Analysis Overview at a Glance

5 Executive Summary of Chronic Pulmonary Hypertension

6 Chronic Pulmonary Hypertension Epidemiology and Market Methodology

7 Chronic Pulmonary Hypertension Epidemiology and Patient Population

8 Chronic Pulmonary Hypertension Patient Journey

9 Chronic Pulmonary Hypertension Treatment Algorithm, Chronic Pulmonary Hypertension Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Pulmonary Hypertension Clinical Trials

11 Chronic Pulmonary Hypertension Marketed Therapies

12 Chronic Pulmonary Hypertension Emerging Therapies

13 Chronic Pulmonary Hypertension: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Pulmonary Hypertension

16 Chronic Pulmonary Hypertension Market Key Opinion Leaders Reviews

18 Chronic Pulmonary Hypertension Market Drivers

19 Chronic Pulmonary Hypertension Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Pulmonary Hypertension Epidemiology 2034

DelveInsight's "Chronic Pulmonary Hypertension - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Pulmonary Hypertension Pipeline 2024

"Chronic Pulmonary Hypertension Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pulmonary Hypertension market. A detailed picture of the Chronic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Pulmonary Hypertension treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pulmonary-hypertension-market-expected-to-rise-2034-compass-pathways-homeostasis-therapeutics-llc-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.